Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NRX Pharmaceuticals (NRXP) Non Operating Income (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Non Operating Income for 2 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 174.99% to $5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$17.4 million through Dec 2025, down 162.36% year-over-year, with the annual reading at -$12.4 million for FY2025, 87.17% down from the prior year.
  • Non Operating Income for Q4 2025 was $5.0 million at NRX Pharmaceuticals, up from -$1.9 million in the prior quarter.
  • The five-year high for Non Operating Income was $5.0 million in Q4 2025, with the low at -$13.9 million in Q2 2025.